Alexion mRNA

Alexion Pharmaceuticals Inc. has an exclusive license to use our proprietary lipid nanoparticle (LNP) technology for use in delivering one of their rare disease messenger RNA (mRNA) programs, which will enable Alexion to address delivery for therapeutic application of mRNA and rapidly enter clinical development.


Under the terms of the March 2017 license agreement, Alexion paid Arbutus $7.5 million upfront, and will pay up to $75 million for achievement of development, regulatory, and commercial milestones, as well as single digit royalties. In addition, Arbutus will conduct technology development and provide manufacturing and regulatory support for the rapid advancement of Alexion's mRNA product candidate, which will be reimbursed by Alexion.